Insider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Purchases 3,600 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel bought 3,600 shares of the company's stock in a transaction dated Friday, April 25th. The shares were acquired at an average price of $9.88 per share, for a total transaction of $35,568.00. Following the acquisition, the chief executive officer now owns 5,570,602 shares in the company, valued at approximately $55,037,547.76. This represents a 0.06 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Snehal Patel also recently made the following trade(s):

• On Thursday, April 17th, Snehal Patel purchased 5,400 shares of Greenwich LifeSciences stock. The shares were acquired at an average cost of $8.98 per share, with a total value of $48,492.00.
• On Monday, April 7th, Snehal Patel acquired 3,600 shares of Greenwich LifeSciences stock. The stock was acquired at an average price of $9.10 per share, for a total transaction of $32,760.00.
• On Friday, April 4th, Snehal Patel purchased 5,500 shares of Greenwich LifeSciences stock. The stock was bought at an average cost of $8.73 per share, for a total transaction of $48,015.00.

Greenwich LifeSciences Trading Up 0.1 %

NASDAQ:GLSI traded up $0.01 on Friday, reaching $9.99. 28,026 shares of the stock traded hands, compared to its average volume of 45,454. The company's fifty day simple moving average is $10.47 and its 200 day simple moving average is $12.15. The company has a market capitalization of $132.61 million, a price-to-earnings ratio of -12.49 and a beta of 1.76. Greenwich LifeSciences, Inc. has a 12 month low of $8.06 and a 12 month high of $18.75.

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported ($0.61) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.40). Equities analysts anticipate that Greenwich LifeSciences, Inc. will post -0.8 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright lifted their price objective on Greenwich LifeSciences from $38.00 to $39.00 and gave the company a "buy" rating in a research note on Monday, April 21st.

Institutional Investors Weigh In On Greenwich LifeSciences

Several institutional investors have recently modified their holdings of GLSI. State Street Corp raised its position in Greenwich LifeSciences by 4.4% in the 3rd quarter. State Street Corp now owns 71,408 shares of the company's stock worth $1,026,000 after buying an additional 3,005 shares during the last quarter. Geode Capital Management LLC raised its stake in Greenwich LifeSciences by 4.6% during the 3rd quarter. Geode Capital Management LLC now owns 133,550 shares of the company's stock valued at $1,919,000 after buying an additional 5,861 shares during the last quarter. Barclays PLC lifted its holdings in shares of Greenwich LifeSciences by 323.3% during the 3rd quarter. Barclays PLC now owns 8,560 shares of the company's stock valued at $123,000 after buying an additional 6,538 shares during the period. Brown Brothers Harriman & Co. purchased a new position in shares of Greenwich LifeSciences in the 4th quarter worth $45,000. Finally, Garden State Investment Advisory Services LLC bought a new stake in shares of Greenwich LifeSciences in the third quarter worth $253,000. 4.16% of the stock is owned by hedge funds and other institutional investors.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.